Ken Griffin Provention Bio, Inc. Transaction History

Citadel Advisors LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$6.7 - $24.21 $3.2 Million - $11.6 Million	477,796 Added 1117.29%	520,560 $12.5 Million
Q4 2022 Feb 14, 2023	SELL	$4.52 - $10.57 $864,052 - $2.02 Million	-191,162 Reduced 81.72%	42,764 $452,000
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $300,135 - $491,766	87,503 Added 59.76%	233,926 $1.05 Million
Q2 2022 Aug 15, 2022	BUY	$3.65 - $7.3 $360,955 - $721,911	98,892 Added 208.06%	146,423 $586,000
Q1 2022 May 16, 2022	SELL	$3.4 - $7.88 $393,737 - $912,543	-115,805 Reduced 70.9%	47,531 $348,000
Q4 2021 Feb 14, 2022	BUY	$5.59 - $7.39 $123,656 - $163,474	22,121 Added 15.66%	163,336 $917,000
Q3 2021 Nov 15, 2021	SELL	$5.66 - $8.33 $183,944 - $270,716	-32,499 Reduced 18.71%	141,215 $904,000
Q2 2021 Aug 16, 2021	BUY	$6.71 - $11.04 $146,324 - $240,749	21,807 Added 14.36%	173,714 $1.46 Million
Q1 2021 May 17, 2021	BUY	$10.12 - $19.45 $1.22 Million - $2.35 Million	121,012 Added 391.69%	151,907 $1.59 Million
Q4 2020 Feb 16, 2021	SELL	$11.79 - $18.94 $367,600 - $590,530	-31,179 Reduced 50.23%	30,895 $523,000
Q3 2020 Nov 16, 2020	BUY	$10.34 - $15.2 $306,529 - $450,604	29,645 Added 91.42%	62,074 $796,000
Q2 2020 Aug 14, 2020	BUY	$7.81 - $17.0 $253,270 - $551,293	32,429 New	32,429 $458,000
Q2 2019 Aug 14, 2019	SELL	$2.3 - $13.79 $38,787 - $232,554	-16,864 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$1.97 - $2.57 $33,222 - $43,340	16,864 New	16,864 $0

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.